IRIDEX Corporation (IRIX)
IRIDEX Corporation is a healthcare company focused on ophthalmic medical technology. The company develops therapeutic laser systems, delivery devices, and consumable instruments used in the treatment of sight-threatening eye diseases. Its product range includes laser consoles for glaucoma and retinal disorders, as well as photocoagulation systems used in procedures involving diabetic retinopathy, macular holes, retinal tears, and retinal detachments. IRIDEX also supplies delivery devices and probes designed for use in office-based and surgical eye care settings. The company sells its products to ophthalmologists, hospitals, surgical centers, research and teaching institutions, government installations, veterinary practices, and office clinics. It serves customers in the United States and through distributors in international markets across Europe, the Middle East, Africa, Asia/Pacific, and the Americas. Founded in 1989 and headquartered in Mountain View, California, the company was previously known as IRIS Medical Instruments, Inc.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IRIX
|
$1.21
|
31.6% Upside
|
Undervalued
|
$2.75
|
198.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-4.9x
|
-12.6x
|
0.3x
|
16.111 M
|
21.66 M
|
16.2%
|
29.1%
|
-2.3
|
—
|
77.4%
|
